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Abstract
Viral resistance to small molecule allosteric inhibitors of CCR5 is well documented, and involves either selection of
preexisting CXCR4-using HIV-1 variants or envelope sequence evolution to use inhibitor-bound CCR5 for entry. Resistance
to macromolecular CCR5 inhibitors has been more difficult to demonstrate, although selection of CXCR4-using variants
might be expected. We have compared the in vitro selection of HIV-1 CC1/85 variants resistant to either the small molecule
inhibitor maraviroc (MVC) or the macromolecular inhibitor 5P12-RANTES. High level resistance to MVC was conferred by the
same envelope mutations as previously reported after 16–18 weeks of selection by increasing levels of MVC. The MVC-
resistant mutants were fully sensitive to inhibition by 5P12-RANTES. By contrast, only transient and low level resistance to
5P12-RANTES was achieved in three sequential selection experiments, and each resulted in a subsequent collapse of virus
replication. A fourth round of selection by 5P12-RANTES led, after 36 weeks, to a ‘‘resistant’’ variant that had switched from
CCR5 to CXCR4 as a coreceptor. Envelope sequences diverged by 3.8% during selection of the 5P12-RANTES resistant,
CXCR4-using variants, with unique and critical substitutions in the V3 region. A subset of viruses recovered from control
cultures after 44 weeks of passage in the absence of inhibitors also evolved to use CXCR4, although with fewer and different
envelope mutations. Control cultures contained both viruses that evolved to use CXCR4 by deleting four amino acids in V3,
and others that maintained entry via CCR5. These results suggest that coreceptor switching may be the only route to
resistance for compounds like 5P12-RANTES. This pathway requires more mutations and encounters more fitness obstacles
than development of resistance to MVC, confirming the clinical observations that resistance to small molecule CCR5
inhibitors very rarely involves coreceptor switching.
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Introduction
Primary transmission of human immunodeficiency virus type 1
(HIV-1) infection is highly selective in two respects. First, it
involves transmission of one or a few genetic variants in spite of the
enormous genetic diversity of HIV-1 in the infected donor
[1,2,3,4]. Second, transmission of HIV-1 strains that use C-C
chemokine receptor 5 (CCR5) as the entry coreceptor is highly
favored [5,6,7,8,9,10], consistent with the observation that
individuals with deletion mutations in the coding region of
CCR5 are highly resistant to HIV-1 infection [11,12,13]. These
results imply that blocking HIV-1 binding to CCR5 is a viable
strategy to prevent transmission, and non-human primate studies
fully support this concept [14,15,16,17,18].
Two classes of CCR5 inhibitors have been developed. The first
reported were amino terminal modifications of the CCR5 native
ligand RANTES that caused CCR5 inhibition by internalization
and sequestration [19,20]. This class of macromolecular CCR5
inhibitors has continued to be developed to generate more potent
inhibitors with more desirable characteristics [21,22,23]. The
second class of CCR5 inhibitors comprise small molecules
[24,25,26,27,28], most of which act by binding to a conserved
site [29,30,31,32] composed of multiple transmembrane domains
of CCR5. The activity of the small molecule inhibitors is thought
to be allosteric displacement of the extracellular domains of CCR5
so that the coreceptor binding regions of CD4-bound envelope no
longer recognize the altered CCR5 configuration [33]. Maraviroc
(Pfizer) was the first of these CCR5 inhibitors to be approved for
clinical use, and has proven to be an effective antiviral agent in
both treatment-naive and treatment-experienced individuals with
predominately CCR5-using (R5) HIV-1 infection [34,35,36].
Resistance to small molecule CCR5 inhibitors arises by two
distinct mechanisms. The most common is selection of pre-existing
minor HIV-1 variants that can use CXCR4 for entry [37,38], and
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change the coreceptor use from CCR5 to CXCR4 has been
demonstrated in vitro [39], but this mechanism of resistance is
infrequent in patients treated with small molecule CCR5 inhibitors
[40]. A less common resistance mechanism is mutation of the
HIV-1 envelope to recognize the altered conformation of
inhibitor-bound CCR5 [39,41,42,43]. This mode of resistance
usually results in cross-resistance to other small molecule CCR5
inhibitors [39,41,44], but not to the macromolecular CCR5
inhibitors [41] despite one early report to the contrary [45] that
was later corrected [41]. Macromolecular CCR5 inhibitors can
select for CXCR4-using viruses [46,47], but no resistance to this
class of inhibitors by HIV-1 that retains entry via CCR5 has been
reported. The report of one chimeric SHIV162P3 variant with
partial resistance to PSC-RANTES [48] has been disputed by a
more recent study [49]. A high barrier to resistance would be
advantageous in the development of anti-HIV-1 compounds
targeting CCR5 for prevention to lower the risk associated with
unrecognized HIV-1 infection. This prompted us to undertake in
vitro selection experiments to compare development of resistance
to the small molecule inhibitor maraviroc [39] and the
macromolecular inhibitor 5P12-RANTES [23].
Results
1. Selection of maraviroc-resistant HIV-1 CC1/85 variants
We chose the HIV-1 R5 isolate CC1/85 [50] for these
experiments because it has been used in multiple prior studies of
resistance to small molecule CCR5 inhibitors [39,41,51,52]. Virus
was passaged weekly in fresh CD8 cell-depleted PBMC cultures
containing increasing concentrations of either MVC or 5P12-
RANTES. We used a very conservative dose escalation schedule
because of multiple prior failures to generate HIV-1 isolates
resistant to either PSC- or 5P12-RANTES (unpublished results).
The concentration of MVC or 5P12-RANTES alternated between
the IC90 concentration (0.24 nM for MVC; 0.12 nM for 5P12-
RANTES) and the IC50 concentration (0.06 nM for MVC;
0.04 nM for 5P12-RANTES) for the first 8 weeks of selection
(Figs. 1A and 2B). Subsequently the inhibitor concentration was
gradually increased to 46 IC90 levels at week 15. During this
period of slow increase in inhibitor concentration, cultures treated
with MVC showed reduced virus replication compared to no
inhibitor controls (Fig. 1A), whereas cultures treated with 5P12-
RANTES showed virus replication comparable to no inhibitor
controls between weeks 6 and 13 (Fig. 2A). Despite this indication
of potential resistance to 5P12-RANTES by week 13, virus
replication ceased during the following 2 weeks despite no increase
in the concentration of 5P12-RANTES (Fig. 2A). During weeks 16
to 18 of selection, replication of virus in MVC-treated cultures
began to approach control levels, and rapid escalation of MVC
concentrations to as high as 1.5 mM failed to inhibit subsequent
replication at weeks 18–23 (Fig. 1A).
We compared the sensitivity of HIV-1 CC1/85 cultured for 18
weeks in the absence of inhibitor to virus cultured for 18 weeks
with escalating concentrations of MVC. The results (Fig. 1B) show
that the infection of PBMC by control virus was fully sensitive to
MVC inhibition, but the MVC-selected virus was resistant to the
highest concentration of MVC tested. We thus confirm the results
of Westby et al. [39] that a CC1/85 variant with greater than
1000-fold resistance to MVC can be selected in 16–18 weeks. We
would not expect cross resistance between small molecule and
macromolecular CCR5 inhibitors, but because of the past
confusion in this area [45], we determined if the highly MVC-
resistant CC1/85 variant had any change in sensitivity to 5P12-
RANTES inhibition. The results of this experiment are shown in
Fig. 1C. The MVC-resistant CC1/85 variant was fully sensitive to
inhibition by 5P12-RANTES, but was cross-resistant to the
allosteric CCR5 inhibitor TAK-779 (data not shown).
2. Sequence evolution associated with MVC-resistance or
5P12-RANTES-induced virus collapse
We isolated full length envelope (env) clones from the control,
MVC-selected, or 5P12-RANTES-selected CC1/85 isolates to
analyze sequence changes associated with resistance in the case of
MVC or impending virus collapse in the case of 5P12-RANTES.
We observed (Table 1) identical changes in the V3 sequences of
both control virus and the highly MVC-resistant virus as reported
by Westby et al. [39] in the majority of their env clones. This not
only confirms their results but also suggests limited evolutionary
pathways to MVC resistance. The sequences from the 5P12-
RANTES-selected viruses showed a mixture of clones with V3
sequence changes identical to the control viruses and clones with
additional V3 changes that may be deleterious in the absence of
compensating mutations elsewhere in envelope [53]. Several env
clones from week 13 of 5P12-RANTES selection with additional
V3 mutations showed diminished ability to mediate infection of
CCR5-expressing target cells in a single cycle assay (Table 1).
3. Prolonged selection attempts to generate 5P12-
RANTES-resistant CC1/85 variants
An effort to rescue 5P12-RANTES resistant virus from week 13,
the last time point with robust virus replication, was made
(indicated by 5P12-RANTES 2 in Fig. 2A). That virus was
propagated without inhibitor for 1 week, and then 5P12-RANTES
selection restarted at 26IC90, the concentration originally present
at week 13. Virus replication continued at reduced levels
compared to no inhibitor controls until week 25, when raising
the 5P12-RANTES concentration to 86 IC90 led to a second
collapse of replication (Fig. 2A). We restarted 5P12-RANTES
selection a third time using virus from week 24 that survived 46
IC90 concentration, and slowly escalated 5P12-RANTES levels
from weeks 25 to 33 of passage (Fig. 2B). Virus replication
increased until week 30, and then diminished when 86 IC90
concentrations were exceeded (Fig. 2A). A fourth (and final) round
of selection was started with virus from week 30, which was
initially cultured with 56IC90 concentrations of 5P12-RANTES.
Virus replication was almost completely inhibited by these
concentrations, so no inhibitor was added for 2 subsequent weeks,
and then a more conservative dose escalation restarted (Fig. 2B). A
major increase in virus replication occurred between weeks 34 and
36 of the fourth round of selection (Fig. 2A). At this time, an
increase in cytopathic effect was noted, suggesting a possible switch
to CXCR4 use. This was evaluated by using sequential virus
isolates from weeks 30 to 44 of selection by 5P12-RANTES and
weeks 36–55 from control cultures to infect activated CD4 T cells
from a CCR5 D32 homozygous donor. Fig. 2C shows that CCR5-
independent infection by 5P12-RANTES selected CC1/85 virus
was first detected at week 36 of round 4 of selection, and improved
substantially during the ensuing six weeks. Surprisingly, a similar
but delayed evolution of CCR5-independent infection occurred in
virus from control cultures without any CCR5 inhibitor added
(Fig. 2C) between weeks 44 and 55 of culture. We confirmed that
infection was mediated by the CXCR4 coreceptor by inhibiting
infection with the CXCR4-specific agent AMD3100 (Fig. 2D).
AMD3100 completely blocked infection by HIV-1 CC1/85 from
weeks 39 and later of 5P12-RANTES selection. By contrast,
AMD3100 was only partially inhibitory for virus recovered from
Resistance to CCR5 Inhibitors
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22020Figure 1. Development of resistance to maraviroc (MVC). A. Weekly increases in p24 capsid antigen (p 24 ng/ml, left y-axis) are plotted for
control cultures with no CCR5 inhibitor (black circles) and cultures with increasing concentrations of MVC (black squares). The MVC concentration inn M
(righty-axis)isindicatedbygrey squares.B.HighlevelresistancetoMVCafter18weeksofselection.Dataaremeanp24capsidantigen(6SEoftriplicate
cultures)plotted against increasing concentrations of MVC for HIV-1 CC1/85 from control cultures (filled circles) or MVC-selected cultures (filled squares).
C. Resistance to MVC does not confer cross-resistance to 5P12-RANTES. Data presented as in panel B, but the inhibitor is 5P12-RANTES rather than MVC.
doi:10.1371/journal.pone.0022020.g001
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using viruses. These data indicate that resistance to 5P12-
RANTES was generated by the selection of virus variants using
CXCR4 for entry, but that this occurred in the context of a virus
population that was evolving towards CXCR4 use even in the
absence of added CCR5 inhibitors.
4. Sequence correlates of CXCR4 use
We explored the evolution of CCR5 and CXCR4 use following
5P12-RANTES selection by evaluating single cycle infection
mediated by CC1/85 env clones isolated after 13 (round 1), 25
(round 2), 30 (round 3), and 36–44 (round 4) weeks of virus
replication (Fig. 3). Entry via CCR5 remained robust with no
difference between control and 5P12-RANTES selected env clones
until week 36 (Fig. 3A). By contrast, entry mediated by CXCR4
was significantly improved for most env clones isolated after 25
(p=0.0016) or 30 weeks (p=0.0231) of 5P12-RANTES selection
compared to entry mediated by CC1/85 env clones from week 0
(Fig. 3B). However, some env clones from control cultures also
showed improved entry via CXCR4 during this time period. At
week 36, there were marked changes in entry efficiency that were
associated with the emergence of distinctive V3 sequences (legend
to Fig. 3). First, the majority of env clones from round 4 of 5P12-
RANTES selection showed reduced entry via CCR5 (Fig. 3A) and
much improved entry via CXCR4 (Fig. 3B). Env clones from
control cultures at week 36 also showed a more modest reduction
in entry via CCR5, but no improvement in entry via CXCR4, and
most had a unique V3 sequence that persisted from week 36 to
week 57. At week 42 of 5P12-RANTES selection, CCR5 entry
had further declined while robust entry via CXCR4 persisted, and
one of two V3 sequences was replaced by a closely related variant.
Env clones from week 42 of control cultures showed a single
Table 1. V3 sequences of control, maraviroc-resistant, and 5P12-RANTES-selected CC1/85 HIV-1 viruses.
Virus Selection V3 sequence CCR5 RLU
a
CC1/85, start CTRPNNNTRKSIHIGPGRAFYATGDIIGDIRQAHC
9 clones ----------------------------------- 7.678
CC1/85, week 18 control
5 clones ------Y------------L--------------- 7.968
3 clones ------Y------------W--------------- 7.880
1 clone -------------------W--------------- 4.945
CC1/85, week 18 MVC-resistant
3 clones ------------------T------V--------- 8.132
2 clones ------------------S------V--------- 8.083
3 clones ------------------S---------------- 8.512
1 clone ------------------T---------------- 8.209
[MVC-resistant clones; Westby et al.]
6 clones ------------------T------V---------
1 clone ------------------S------V---------
CC1/85, week 13 control
4 clones ------Y------------L--------------- 7.969
3 clones -------------------L--------------- 7.752
CC1/85, week 13 5P12-RANTES
8 clones ------Y------------L--------------- 7.910
1 clone ----------------------------------- 7.950
1 clone ------------L--------P------------- 4.713
1 clone ------Y------------L-------E------- 4.241
1 clone ------Y-K-----E--K-L-------EN-K---- 4.395
aLog10 relative light units (RLU) in single cycle infection of NP-2.CD4.CCR5 cells mediated by envelope (env) clones with the indicated V3 sequence. Mean values for
multiple env clones with the same V3 sequence, representative single values for individual clones. Note that env clones with the same V3 sequence may differ in
sequence in other regions of envelope.
doi:10.1371/journal.pone.0022020.t001
Figure 2. Development of resistance to 5P12-RANTES (5P12). A. Weekly increases in p24 capsid antigen during four successive rounds of
selection: 5P12 1 (blue, weeks 1–15); 5P12 2 (green, weeks 13–25); 5P12 3 (purple, weeks 24–33); and 5P12 4 (brown, weeks 30–44). Control cultures
with no inhibitor are shown in black filled circles. B. Increasing concentrations of 5P12 expressed as multiples of the 90% inhibitory concentration
(IC90=0.12 nM) for each of the four rounds of selection, with colors matching panel A. C. Replication of viruses from indicated weeks of selection on
activated CD4
+ T cells from a CCR5D32 homozygous donor. Values are mean p24 capsid antigen levels (6 SE of triplicate cultures) after 7 days of
culture. D. Viruses from the indicated weeks of 5P12-RANTES round 4 of selection (5P12 4) or control cultures with no inhibitors were used to infect
activated CD4
+ T cells from normal donors in the presence of the CXCR4 blocking agent AMD3100 (AMD). The percent inhibition by AMD3100 of p24
capsid antigen levels after 7 days of culture is plotted versus the week of virus isolation.
doi:10.1371/journal.pone.0022020.g002
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22020Figure 3. Entry efficiency via CCR5 versus CXCR4. Full length envelope (env) clones were generated after the indicated weeks of selection by
5P12-RANTES (grey or colored filled symbols, weeks in bold) or control cultures with no inhibitors (solid symbols, weeks not bold), and used to
mediate entry of an env-negative reporter construct into NP-2.CD4.CCR5 target cells (square symbols, panel A) or NP-2.CD4.CXCR4 target cells (circles,
panel B). Entry efficiency was determined by luciferase expression, which is plotted as log10 relative light units (log RLU). Each symbol is the entry
result for an individual env clone, and the mean 6 SE for all env clones is indicated by the bold horizontal line and error bars. Rapid sequence
evolution occurred between weeks 30 and 36 of culture, and V3 sequences that evolved are color-coded in the legend, and matched to the entry
data for each env clone with the designated sequence. The top V3 sequence predominated in both the control and 5P12-RANTES selected viruses
isolated at week 30, but only three env clones retained that sequence at week 36 (indicated by black/red symbols). This V3 sequence differed from
the starting CC1/85 sequence by the two amino acids indicated in red. The four amino acid deletion in V3 observed in control cultures is indicated by
xxxx. The starting sequence that gave rise to CXCR4-using variants (clone #11) is indicated in panel A and B at week 0 by the half-filled symbol (see
Fig. 4). The single clones from week 13 with poor entry function on both CCR5 (Table 1) and CXCR4 are not shown in this figure.
doi:10.1371/journal.pone.0022020.g003
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that was associated with a unique V3 sequence with a four amino
acid deletion (loss of ATGD, positions 318–321). Env clones from
week 44 of 5P12-RANTES selection had identical V3 sequences
associated with very poor entry via CCR5 and robust entry via
CXCR4. In addition to the six amino acid changes in the V3
region, these env clones also had two shared substitutions in C2,
I272V and N277D. The latter substitution eliminates a potential
N-linked glycosylation site. Control env clones from week 44 were
mainly derived from the four amino acid deletion variant first
identified at week 42, and were still relatively poor at entry via
CXCR4. These were replaced with closely related sequence
variants that added charged arginine residues in V3 that improved
their entry function via CXCR4. However, some sequence
variants first identified at week 36 persisted, and these were better
at entry via CCR5 than CXCR4. These results are consistent with
the AMD3100 inhibition results in Fig. 2D, confirming the co-
existence of both R5 and X4 variants within the control virus
population.
5. Envelope sequence evolution to CXCR4 use
Since both prolonged selection with 5P12-RANTES and
prolonged culture without added CCR5 inhibitors led to the
emergence of CXCR4-using viruses, we were interested in
determining if the evolution of CXCR4 use was similar or
different for the two groups. Full length gp160 sequences were
obtained for the majority of env clones used in single cycle infection
assays depicted in Fig. 3. The phylogenetic tree of the amino acid
sequence of all env clones on the pathway to CXCR4 use in both
5P12-RANTES selected viruses and control viruses is shown in
Fig. 4A. The tree is rooted by one of two distinct env sequences
present in the starting CC1/85 isolate with a motif sequence in the
C5 region that was retained by all later env clones, both CCR5-
and CXCR4-using, on this tree. The sequences from viruses under
5P12-RANTES selection cluster together at the top of the tree,
and are closely related to a set of CCR5-using env clones present at
weeks 25 and 30 of selection. There was a mean divergence of
3.8% from the starting sequence at week 36 of selection. The
sequences of control viruses capable of CXCR4 use clustered in
the middle of the tree, and had a mean divergence of 2.8% from
the starting sequence at week 44 of culture. The env clones that
retained only CCR5 use clustered together closer to the starting
sequence. Fig. 4B gives the entry efficiency via CCR5 and
CXCR4 mediated by env clones from weeks 36, 42, and 44 for
both the 5P12-RANTES selection and control viruses. The data
plotted in Fig. 4B emphasizes that the sequence differences
depicted in Fig. 4A led to distinct entry phenotypes. All env clones
from cultures under 5P12-RANTES selection (except one from
week 36, depicted by the red/black filled symbol in Fig. 3)
mediated robust entry via CXCR4 and diminishing entry via
CCR5. By contrast, env clones from control cultures were better at
mediating entry via CCR5 and entry via CXCR4 improved only
modestly as entry via CCR5 declined. The selection pressure
exerted by 5P12-RANTES thus led to a transient appearance of
R5X4 viruses, followed by their evolution to X4 only. The virus
Figure 4. Env (gp160) sequence evolution to CXCR4 use. A. A
phylogenetic tree representing the env clones that evolved from CCR5
to CXCR4 use. The tree is rooted with one of two variants found in the
starting CC1/85 virus population with a TNNTxN motif sequence at
position 459–465 (HXB2 numbering) in C5 instead of NDTSGT. All env
clones that developed CXCR4 use were derived from this founder
sequence. The weeks at which the env clones were isolated is indicated
by the symbol legend, and the V3 sequence is indicated by the color
given in the legend to Fig. 3. All env clones from week 36 and later of
5P12-RANTES selection were capable of using CXCR4 (see below),
whereas only a subset of control env clones from week 44 or later were
capable of entry via CXCR4. B. Entry data for env clones from weeks 36,
42, and 44 either from control cultures (open symbols) or 5P12-RANTES
containing cultures (closed symbols, weeks depicted as in Fig. 4A). The
symbols are color coded as in Figs. 3 and 4A.
doi:10.1371/journal.pone.0022020.g004
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complex, with a predominance of R5 viruses, some R5X4 viruses,
and only a few weak X4 viruses.
The sequence evolution from CCR5 to CXCR4 coreceptor use
was driven by mutation, and the rate of mutation is proportional
to the number of viral replication cycles, not the weeks of virus
culture. Replication was initially reduced by addition of MVC (see
Fig. 1A) or 5P12-RANTES (see Fig. 2A) in each round of
selection. Table 2 presents the translation of cumulative p24
capsid antigen levels (AUC, area under curve from Fig. 2A) to
cycles of replication to correct for the reduced replication in the
presence of inhibitors. These corrections indicate that the
emergence of CXCR4 use at week 36 during round 4 of 5P12-
RANTES selection occurred after 150 cycles of replication,
whereas the spontaneous emergence of CXCR4 use in control
cultures at week 44 occurred after 308 cycles of replication
(Table 2). We also calculated the observed versus expected
number of nucleotide substitutions for the envelope gene using the
mutation rate/base pair/cycle recently determined by Abram et
al. [54]. The result (Table 2) suggests strong directional selection
for the mutations associated with resistance to 5P12-RANTES,
whereas the evolution to CXCR4 use in control cultures is more
consistent with neutral drift. We also determined if the levels of
RANTES present in the medium during virus passage might select
for CXCR4 use, and the peak values were too low (,1.15 ng/ml)
in these CD8 T cell-depleted cultures to inhibit virus entry via
CCR5 [55].
Discussion
Our primary finding is that resistance to the small molecule
CCR5 inhibitor MVC could be generated in the same time frame
and by the same apparent mechanism as previously described
[39], whereas resistance to the macromolecular CCR5 inhibitor
5P12-RANTES developed only after four successive rounds of
selection (the first three resulting in virus extinction) by coreceptor
switching to CXCR4. However, this route to resistance must be
viewed in the context of control cultures where virus evolution to
the use of CXCR4 as a coreceptor also occurred, albeit at a slower
pace, with fewer and different envelope mutations, and with better
preservation of CCR5 use.
The MVC-resistance results presented in Figure 1 confirm the
prior observations [39,45,51] that HIV-1 CC1/85 develops
resistance to small molecule CCR5 inhibitors while retaining use
of CCR5. Other HIV-1 isolates, notably HIV-1 SF162, can
escape small molecule CCR5 inhibitors by either switching to
CXCR4 [39] or by selection of pre-existing CXCR4-using
variants [56]. In vitro selection of small molecule CCR5
inhibitor-resistant isolates that retain use of drug-bound CCR5
is generally associated with relatively few mutations in the V3
region [39,57], although there are notable exceptions to this
finding [58]. Our replication of the results of Westby et al. [39]
confirms that only two replacement mutations in V3 contribute
substantial resistance to MVC (Table 1). We did not observe the
three additional changes noted by Westby et al. (T163K, N355Y,
S405A) in MVC-resistant env clones, nor did we isolate the minor
population of MVC-resistant viruses with three mutations in V3,
but we did observe the N355Y and S405A changes in a subset of
env clones from control cultures. We postulate that the two V3
mutations necessary for MVC resistance of the CC1/85 isolate
are fewer than the eight critical mutations (six in V3 and two in
C2) associated with resistance to 5P12-RANTES by CXCR4 use
(Figs. 3 and 4), and thus that recognition of MVC-bound CCR5
is favored over coreceptor switching in the development of
resistance in vitro.
Extensive sequence evolution in the V3 region and compen-
satory changes in other regions of env are generally required for
the CCR5 to CXCR4 coreceptor switch [53,59,60], and was
observed in these experiments both with the selective pressure of
adding 5P12-RANTES as well as in control virus cultures.
Acquisition of resistance to AOP-RANTES was previously
observed to be associated with coreceptor switching that
required only two V3 mutations [46], but that result was
confounded by the choice of the virus isolate which was derived
from a CXCR4-using parental strain that was converted to
CCR5 use by V3 mutation, and the CXCR4-using variant
quickly reverted to CCR5 use when AOP-RANTES was
removed [61]. By contrast, 5P12-RANTES selected, CXCR4-
using variants in the current experiments failed to revert to
CCR5 use when propagated for up to two months in the
absence of inhibitor. We chose to study resistance to 5P12-
RANTES in the CC1/85 strain because it was a patient isolate
Table 2. Calculation of virus replication cycles during selection.
Control 5P12 round 1 5P12 round 2 5P12 round 3 5P12 round 4
First week 1 1 15 25 31
Last week 58 15 28 36 44
AUC
1 7044 802 851 945 1720
Increase/week 121.45 53.46 65.46 85.91 132.21
% Control (100) 44.02 53.90 70.74 108.94
Replication Cycles
2 406 46.22 49.05 54.47 99.14
Weeks to X4 switch 44 36





1AUC; area under curve for cumulative increase in capsid p24 antigen shown in Fig. 2A for the indicated number of weeks (first to last).
2Calculation of replication cycles assume 1 cycle/day for HIV-1 CC1/85 in control cultures [66], and is corrected for weeks of replication (i.e., allowing for pauses) and
diminished p24 levels (% control) for cultures under 5P12-RANTES (5P12) selection.
3Expected mutations are calculated based on the rate found by Abram et al. [54] of 1.4610
25 mutations/bp/cycle and the 2553 bp target envelope gene.
4Observed mutations are the mean number of nucleotide mutations observed in all envelope molecular clones with confirmed entry via CXCR4.
doi:10.1371/journal.pone.0022020.t002
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inhibitors [39,41,51,52] and it displayed robust replication in
vitro (see Fig. 2A). However, virus isolated from the same
subject a year later (CC2/86) had undergone coreceptor
switching to CXCR4 [50], so the CC1/85 population of viruses
may have contained some intermediates that were exploring
CXCR4 entry. The data in Fig. 3B indicate that many of the env
clones from the starting CC1/85 virus stock could mediate entry
via CXCR4 at levels well above background, even though no
virus capable of infecting primary T cells from a CCR5 D32
homozygous donor was isolated until week 36 of 5P12-
RANTES selection or week 44 from control cultures (Fig. 2C).
T h ef a c tt h a tC X C R 4u s ee v o l v e di nc o n t r o lc u l t u r e sb y4 4
weeks of passage (as compared to 56 weeks in the infected
subject) is consistent with precursors with modest CXCR4 use
being present in the starting CC1/85 isolate. Prolonged culture
of virus is also known to influence the entry phenotype [62], and
it is clear from Fig. 4A that virus from control cultures
underwent considerable sequence divergence although not as
much as virus under 5P12-RANTES selection pressure. Virus
under selection by 5P12-RANTES showed strong evidence of
positive selection of envelope mutations, whereas virus isolated
from control cultures had fewer mutations and did not appear to
be under strong selection (Table 2). Indeed, the agreement
between the predicted number of nucleotide substitutions
derived from an artificial lacZ target sequence [54] and the
number of observed mutations in the env gene of control virus
(Table 2) is an independent confirmation of the in vitro HIV-1
mutation rate. The combination of V3 and C2 mutations
associated with coreceptor switching in both the 5P12-RANTES
selected variants and the X4 variants from control cultures have
not been observed previously, although the deletion of the
ATGD V3 sequence that appeared in control virus is similar to
a laboratory deletion of IIGD (D26–29) in HIV-1 clone R3A
that was also observed to impair entry via CCR5 but preserve
entry via CXCR4 [63].
A striking result of our studies was the repeated collapse of virus
replication after the development of apparent partial resistance to
5P12-RANTES. Some env clones from weeks 13 of 5P12-
RANTES selection showed diminished entry function via CCR5
(Table 1) as did many env clones from week 36 and later (Fig. 3A).
A minority of env clones from control (no inhibitor) cultures also
mediated poor entry via CCR5 (Table 1). These results suggest
that selection by 5P12-RANTES may result in some viral variants
with reduced binding of CCR5, which would result in increased
sensitivity to inhibition, a plausible explanation for their transient
appearance. It is worth noting that we have previously observed
increased sensitivity to CCR5 inhibitors at the time of coreceptor
switching in an infected subject [60], and many coreceptor switch
intermediates show diminished entry via both CCR5 and CXCR4
[59]. This observation is confirmed by the data shown in Fig. 3,
where it is obvious that entry via CCR5 begins to diminish as
CXCR4 entry is gained in both 5P12-RANTES selected and
control cultures. Thus one explanation for the virus extinction at
the end of the first three rounds of selection is that evolution
towards CXCR4 use involves intermediates with increased
sensitivity to CCR5 inhibitors.
These results confirm that the only apparent route to resistance
to macromolecules like 5P12-RANTES appears to be virus
evolution to CXCR4-mediated entry. In the setting of prevention
trials, the blocking of CCR5 should prevent infection and the
initiation of the long and difficult evolution to CXCR4 use.
Neither small or large molecule CCR5 inhibitors would prevent
the rare transmission of X4 variants [6,9].
Materials and Methods
Ethics statement
Whole venous blood was collected from anonymous donors
participating in The Scripps Research Institute volunteer donor
pool. Written informed consent was obtained from all donors and/
or their legal guardians, and the protocol was approved by the
Scripps Health Institutional Review Board.
CCR5 inhibitors and virus
Maraviroc (MVC) was kindly provided by Hernan Valdez
(Pfizer, New York, NY). 5P12-RANTES was prepared by
chemical synthesis as described [23]. The R5 HIV-1 isolate
CC1/85 was kindly provided by Shawn Kuhmann and John
Moore (Cornell University, New York, NY).
Virus passage
Virus was propagated using pooled CD8
+ T cell-depleted
PBMC from 4 donors who were heterozygous for the CCR5 D32
mutation to increase the susceptibility of target cells to CCR5
inhibitors. The same 4 donors were used throughout the
experiment. PBMC were CD8
+T cell-depleted by negative
selection using anti-CD8 antibody (BD, Palo Alto, CA) and
binding to BioMag beads (Qiagen), followed by stimulation for two
days with 2 mg/ml PHA followed by two days with 20 units/ml IL-
2 in RPMI 1640 medium with 10% fetal bovine serum (FBS). Fifty
percent inhibitory concentrations (IC50) and 90 percent inhibitory
concentrations (IC90) of MVC or 5P12-RANTES were deter-
mined using the pooled CD8
+ T cell-depleted PBMC before
starting the experiment. Infection was started by adding 1000
TCID50/ml CC1/85 to 20 ml of PBMC at 2610
6/ml. Every
week 5 ml of cell-free supernatant from the prior week’s culture
was added to 15 ml of freshly stimulated CD8-depleted PBMC
[51] that were untreated (control) or had been incubated with
MVC or 5P12-RANTES at the indicated concentration for
30 minutes. Five ml of IL-2-containing medium was added
midweek to support robust virus replication. Each week medium
and cells were frozen for subsequent assays, and p24 viral capsid
antigen was measured by ELISA (Perkin Elmer, Waltham, MA).
Blood from a CCR5 D32 homozygote was obtained from an
anonymous adult donor participating in the volunteer donor
program of The Scripps Research Institute. PBMC were separated
by Ficoll-Hypaque density sedimentation and stimulated two days
with 2 mg/ml PHA followed by 2 days with 20 units/ml IL-2 in
RPMI 1640 medium with 10% FBS. These cells were used to
check infectivity of viruses from the control and the 5P12-
RANTES treated cultures.
Envelope Cloning and Pseudovirus Coreceptor Typing
The gp160 envelope gene was amplified from cellular DNA
using primer pair envA and envM as previously described [64].
The 3KB PCR fragments were cloned into an expression vector
(pcDNA3.1, Invitrogen) and co-expressed with the NL4.3 env-
negative, luciferase-positive reporter plasmid [65] in 293T cells.
Coreceptor use of viruses or envelope clones was evaluated by
infection of NP2.CD4.CCR5 and U87.CD4.CXCR4 cell lines
that were maintained in DMEM with 10% FBS, 1 mg/ml
puromycin and 500 mg/ml of G418. The luciferase activities were
determined as previously described [59], and are reported as
relative light units (RLU).
Genotypic analysis
Sequences were compiled and visualized using Lasergene 8.1
software (DNASTAR, Madison, WI). Sequences were aligned with
Resistance to CCR5 Inhibitors
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22020ClustalX and manually edited using BioEdit (version 7).
Phylogenetic analysis were determined using MEGA (version
3.1; Molecular Evolutionary Genetics Analysis). Sequences of full
length env clones will be deposited to GenBank upon acceptance of
the manuscript.
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